{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Grade+IV+Glioma&page=3", "query": { "condition": "Recurrent Grade IV Glioma", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 103, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Grade+IV+Glioma&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Grade+IV+Glioma&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T20:38:20.440Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05789394", "title": "Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Glioblastoma, IDH-Wildtype", "Recurrent Astrocytoma, IDH-Mutant, Grade 4", "Astrocytoma, Grade IV" ], "interventions": [ { "name": "Allogeneic Adipose-derived Mesenchymal Stem Cells", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Craniotomy", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Ommaya Reservoir Tap", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2023-06-16", "completion_date": "2027-07-24", "has_results": false, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-10-04T20:38:20.440Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05789394" }, { "nct_id": "NCT07416188", "title": "Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Glioblastoma", "Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype", "Relapsed Cancer", "Recurrent Tumor", "Glioblastoma Multiforme", "Recurring Glioblastoma", "Brain and Central Nervous System Tumors", "Glioma", "Glioblastomas", "Grade IV Astrocytoma", "GBM", "Recurrent Glioma (Glioblastoma Multiforme)", "High Grade Glioma", "Glioma, Malignant", "Brain Cancer" ], "interventions": [ { "name": "LMP744", "type": "DRUG" }, { "name": "Conventional Surgery or Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 40, "start_date": "2026-07-15", "completion_date": "2032-12-31", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-04T20:38:20.440Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07416188" }, { "nct_id": "NCT01906385", "title": "Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioma" ], "interventions": [ { "name": "Rhenium Liposome Treatment", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cerenome", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2015-06-03", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2025-03-26", "last_synced_at": "2026-10-04T20:38:20.440Z", "location_count": 3, "location_summary": "Manhasset, New York • Dallas, Texas • San Antonio, Texas", "locations": [ { "city": "Manhasset", "state": "New York" }, { "city": "Dallas", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01906385" }, { "nct_id": "NCT04489420", "title": "Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Astrocytoma, Grade IV", "Giant Cell Glioblastoma", "Glioblastoma Multiforme", "Cyclophosphamide", "Immunosuppressive Agents", "Immunologic Factors", "Physiological Effects of Drugs", "Molecular Mechanisms of Pharmacological Action", "Antiviral Agents", "Anti-infective Agents", "Analgesics, Non-narcotic", "Analgesics", "Sensory System Agents", "Peripheral Nervous System Agents" ], "interventions": [ { "name": "CYNK001-IV", "type": "BIOLOGICAL" }, { "name": "CYNK001-IT", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Celularity Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2020-10-01", "completion_date": "2021-08-10", "has_results": false, "last_update_posted_date": "2022-08-10", "last_synced_at": "2026-10-04T20:38:20.440Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04489420" }, { "nct_id": "NCT02343406", "title": "Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Depatuxizumab mafodotin", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Lomustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "99 Years", "sex": "ALL", "summary": "Up to 99 Years" }, "enrollment_count": 266, "start_date": "2015-02-17", "completion_date": "2019-06-24", "has_results": true, "last_update_posted_date": "2020-05-22", "last_synced_at": "2026-10-04T20:38:20.440Z", "location_count": 13, "location_summary": "Palo Alto, California • Aurora, Colorado • Denver, Colorado + 9 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02343406" }, { "nct_id": "NCT04327011", "title": "A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma Multiforme", "Astrocytoma", "Gliomas, Malignant" ], "interventions": [ { "name": "Toca 511 vector", "type": "BIOLOGICAL" }, { "name": "Toca FC • Flucytosine • 5-FC • 5-Fluorocytosine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Tocagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2011-02", "completion_date": "2019-12", "has_results": false, "last_update_posted_date": "2020-03-30", "last_synced_at": "2026-10-04T20:38:20.440Z", "location_count": 11, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Edison", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04327011" }, { "nct_id": "NCT03194971", "title": "NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Tumor samples from patients treated with TTFields at initial diagnosis.", "type": "OTHER" }, { "name": "Tumor samples from patients treated with TTFields at tumor recurrence.", "type": "DEVICE" } ], "intervention_types": [ "OTHER", "DEVICE" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2017-06-01", "completion_date": "2023-06-04", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-10-04T20:38:20.440Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03194971" }, { "nct_id": "NCT01966809", "title": "Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Tumor, Recurrent" ], "interventions": [ { "name": "Photofrin photodynamic therapy.", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Harry T Whelan, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2015-06", "completion_date": "2017-12-19", "has_results": true, "last_update_posted_date": "2019-08-20", "last_synced_at": "2026-10-04T20:38:20.440Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01966809" }, { "nct_id": "NCT07831369", "title": "VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "Astrocytoma, IDH-Mutant, Grade 4" ], "interventions": [ { "name": "Valproic Acid (VPA)", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Simvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inova Health Care Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "98 Years", "sex": "ALL", "summary": "18 Years to 98 Years" }, "enrollment_count": 52, "start_date": "2026-09-04", "completion_date": "2030-12-30", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-04T20:38:20.440Z", "location_count": 1, "location_summary": "Fairfax, Virginia", "locations": [ { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07831369" }, { "nct_id": "NCT00069940", "title": "Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Gastrointestinal Stromal Tumor", "Sarcoma" ], "interventions": [ { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "telomerase: 540-548 peptide vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": null, "start_date": "2000-12", "completion_date": "2008-08", "has_results": false, "last_update_posted_date": "2010-12-28", "last_synced_at": "2026-10-04T20:38:20.440Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00069940" } ] }